Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449722
Status:
COMPLETED
Last Update Posted:
2016-01-21
First Post:
2007-03-20
Brief Title:
OD vs TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
Sponsor:
Dr Falk Pharma GmbH
Organization:
Dr Falk Pharma GmbH
Study Overview
Official Title:
Double-blind Double-dummy Randomised Multicentre Comparative Study of the Efficacy and Tolerability of Once Daily 30 g Mesalazine Granules Versus Three Times Daily 10 g Mesalazine Granules in Patients With Active Ulcerative Colitis
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To proof the therapeutic equivalence of once daily OD versus three times daily TID dosing of total 30 g mesalazine granules in patients with active ulcerative colitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-001216-31 | None | None | None |